Premium
Seminal vesicles of infertile patients with male accessory gland infection: ultrasound evaluation after prolonged treatment with tadalafil, a selective phosphodiesterase‐5 inhibitor
Author(s) -
La Vignera S.
Publication year - 2013
Publication title -
andrologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.633
H-Index - 59
eISSN - 1439-0272
pISSN - 0303-4569
DOI - 10.1111/and.12027
Subject(s) - tadalafil , medicine , seminal vesicle , urology , ultrasound , erectile dysfunction , prostate , semen analysis , semen , placebo , sperm , infertility , andrology , pathology , biology , radiology , pregnancy , genetics , alternative medicine , cancer
Summary The aim of this study was to investigate possible ultrasound seminal vesicle ( SV ) changes in infertile patients with ‘hypertrophic‐congestive’ ( HCUF ) or ‘fibro‐sclerotic’ ( FSUF ) ultrasound form of male accessory gland infection ( MAGI ) after prolonged administration of tadalafil ( TAD ), a selective phosphodiesterase‐5 inhibitor. Forty infertile patients with HCUF and 40 patients with FSUF and erectile dysfunction were selected and arbitrarily divided into two groups, who were prescribed TAD 5 mg daily for 3 months, the first 20 consecutive patients with HCUF (group A1) or FSUF (group A2) or placebo, the second 20 consecutive patients with HCUF (group B1) or FSUF (group B2). All patients underwent scrotal and prostate‐vesicular transrectal ultrasound evaluation and semen analysis ( WHO , 2010) before and after treatment. Group A1 patients showed a significant reduction in fundus/body ratio and higher pre‐ and post‐ejaculatory body SV antero‐posterior diameter difference compared with the other three groups. These patients showed also a significant increase in SV ejection fraction and a significant improvement in the total sperm count, progressive motility, seminal levels of fructose and ejaculate volume. These results suggest that infertile patients with HCUF had an improvement in SV ultrasound features suggestive of chronic inflammation after daily treatment with low doses of TAD .